(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 10.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.15%.
Bioage Labs's earnings in 2026 is -$107,797,000.On average, 13 Wall Street analysts forecast BIOA's earnings for 2026 to be -$115,470,754, with the lowest BIOA earnings forecast at -$131,064,476, and the highest BIOA earnings forecast at -$103,268,770. On average, 13 Wall Street analysts forecast BIOA's earnings for 2027 to be -$106,072,239, with the lowest BIOA earnings forecast at -$140,522,737, and the highest BIOA earnings forecast at -$13,511,802.
In 2028, BIOA is forecast to generate -$121,440,764 in earnings, with the lowest earnings forecast at -$153,855,301 and the highest earnings forecast at -$86,379,018.